Find a lawyer
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod.
After a solid year in 2023, we assess how private capital and digital transition will shape the sector’s prospects in 2024
Higher borrowing costs and economic turbulence made for a subdued 2023, but 2024 should prove busier
2024 should see an uptick in deals across the sector but regulatory attention is never far away
Despite economic and geopolitical disruption last year, biopharma M&A remained resilient and looks set for a busy 2024
Heightened interest rates have dampened enthusiasm for M&A and raised questions on how to fund deals
Explore all sub topics
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod.